Lab Values
Regulatory
RANDOM :)
Acronyms
100

This lab value is commonly monitored to detect or monitor the progression of prostate cancer 

Prostate Specific Antigen(PSA)

100

This institutional system houses all Reg files and TMF for protocols. 

Advarra eREG

100

In the EPIC AE module, Adverse Events are routed to this team member for sign off and finalization. 

Treating MD

100

any expected or unexpected adverse event, related or unrelated to the therapy being studied, that results in any of the following outcomes: death, a life-threatening adverse event, requires inpatient hospitalization (not required as part of the treatment) or prolongation of existing hospitalization, a persistent or significant disability or incapacity, or cancer, or a congenital anomaly or birth defect.

Serious Adverse Event (SAE)

200

Anemia can be caused by low levels of this blood cell count

Hemoglobin (Hb)

200

****Monitoring Visit logs are saved to this system 

Advarra eREG/ Sharepoint for older trials that are not transitioned to Advarra eReg

200

filing of SAE communication with sponsor/supporter are kept in this system 

Advarra  eREG

200

A meeting that prepares a research site for a clinical trial.  Held between a study sponsor's representative and the research team at a potential clinical trial site, where the protocol, procedures, and study details are reviewed to ensure the site is prepared to begin enrolling patients in the study

site initiation visit (SIV)

300

This AE means there is an abnormally low amount of platelets.

Thrombocytopenia

300

the ongoing periodic evaluation of a research study by an Institutional Review Board (IRB) after initial approval, where the IRB assesses the study's progress, safety of participants, and adherence to the protocol at designated intervals throughout the study duration, typically on an annual basis, to ensure ethical conduct and participant protection.

Continuing Reviews 

300

An RNI is submitted in this system. 

OneIRB
300

These 4 categories of responses can be given as a RECIST response. 

  • Complete response (CR): Disappearance of all measurable lesions. 
  • Partial response (PR): At least a 30% reduction in the sum of the longest diameters (LD) of target lesions. 
  • Stable disease (SD): Neither a 30% reduction nor a 20% increase in the sum of LD. 
  • Progressive disease (PD): A 20% increase in the sum of LD or the appearance of new measurable lesions. 
400

When Potassium (K) levels are low, this Adverse Event should be logged.

Hypokalemia

400

All GU study SAE logs are maintained in this system 

Prometheus 

400

advocated to control bias that might result from errors in progression assessments.  Has driven the requirement to have scans read by a central group of radiologists who are blinded to treatment arm, the local investigator assessment of progression and other clinical outcomes.

blinded, independent, central review (BICR)

500

low Sodium (Na) levels often result in this adverse event to be documented. 

hyponatremia

500

A group of doctors, scientists, and other experts that reviews the detailed plan of a clinical trial for scientific quality and correct study design.

Scientific Review Committee (SRC) 

M
e
n
u